Patients after myocardial infarction with chronic heart failure with preserved left ventricular ejection fraction: the issue of prescribing beta blockers. The results of a 2-year prospective study
- Authors: Averyanova E.V.1, Chernova A.A.1, Vershinina O.D.1, Oleynikov V.E.1
-
Affiliations:
- Penza State University
- Section: Original Research Articles
- Submitted: 18.03.2025
- Accepted: 28.04.2025
- Published: 25.06.2025
- URL: https://medjrf.com/0869-2106/article/view/677312
- DOI: https://doi.org/10.17816/medjrf677312
- ID: 677312
Cite item
Abstract
Aim. To study a 2-year catamnesis in patients with myocardial infarction (MI) with heart failure (HF) with preserved LVEF who received/did not receive beta-blockers (ВВ).
Materials and methods. 127 MI patients aged 53 (48; 60) years with preserved LVEF were included. On the 4th-9th day of MI, after 12 and 24 months, echocardiography with assessment of global longitudinal deformation (GLS), multi-day monitoring of the electrocardiogram (MMECG), the level of N-terminal propeptide of natriuretic hormone was determined, and a 6-minute walking test was performed. The end point was considered to be the progression of HF over the next 2 years.
Results. 29 (23%) patients did not receive BB due to hypotension and bradycardia – the "without BB" group, the other 98 (77%) who received BB formed the "BB" group. In the "BB" group, by the 2nd year of the post-infarction period, there was an increase in indexed indices of final diastolic and systolic volumes, a decrease in LVEF by 3.1% (p=0.00077) and GLS by 2.4% (p=0.0002), in the "without BB" group, these parameters remained stable.
In patients of the BB group, a decrease in chronotropic load on the myocardium and an increase in the circadian index were recorded while maintaining its rigid level. In the group of patients "without BB", an increase in chronotropic load and normalization of the circadian rhythm profile were noted by 12 months after MI.
The number of patients with progressive HF over 2 years of follow-up in the "BB"/"without BB" groups did not differ: in 21% and 24%, respectively (RR=0.659 (95% 0.35-1.243)
Conclusion. In the group of patients with HF with preserved LVEF who did not take BB, a more stable state of the volume and deformation characteristics of the myocardium was noted for 2 years after MI, normalization of the circadian heart rhythm profile was observed, and no significant differences in the frequency of HF progression were found.
Full Text

About the authors
Elena Vladimirovna Averyanova
Penza State University
Email: averyanova-elena90@bk.ru
ORCID iD: 0000-0001-9925-2096
кандидат медицинских наук, доцент кафедры "Терапия"
Russian Federation, Krasnaya str., 40, Penza, 440026, RussiaAngelina Andreyevna Chernova
Penza State University
Email: angelinakorneeva170498@gmail.com
ORCID iD: 0009-0002-7957-8034
аспирант очной формы обучения кафедры «Терапия»
Russian Federation, Krasnaya str., 40, Penza, 440026, Russia.Olga Dmitrievna Vershinina
Penza State University
Email: poloz.ol@yandex.ru
ORCID iD: 0000-0002-4127-6607
аспирант очной формы обучения кафедры «Терапия»
Russian Federation, Krasnaya str., 40, Penza, 440026, Russia.Valentin Elivich Oleynikov
Penza State University
Author for correspondence.
Email: v.oleynikof@gmail.com
ORCID iD: 0000-0002-7463-9259
доктор медицинских наук, профессор, заведующий кафедрой «Терапия»
Russian Federation, Krasnaya str., 40, Penza, 440026, RussiaReferences
- Российское кардиологическое общество. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(11): 4103. [Russian Society of Cardiology. Acute myocardial infarction with ST segment elevation electrocardiogram. Clinical guidelines 2020. Russian Journal of Cardiology. 2020; 25(11): 4103. (in Russ.)]. doi: 10.15829/29/1560-4071-2020-4103.
- Барбараш О.Л., Дупляков Д.В., Затейщиков Д.А. и др. Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2021; 26(4): 4449. [Barbarash O.L., Duplyakov D.V., Zateyshikov D.A. and others. Acute coronary syndrome without ST segment elevation electrocardiogram. Clinical guidelines 2020. Russian Journal of Cardiology. 2021; 26(4): 4449. (in Russ.)] doi: 10.15829/1560-4071-2021-4449
- Freemantle N, Cleland J, Young P et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999; 318(7200): 1730-1737. doi: 10.1136/bmj.318.7200.1730
- Szummer K, Wallentin L, Lindhagen L, et al. Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. Eur Heart J. 2018;39(42):3766-3776. doi: 10.1093/eurheartj/ehy554
- Szummer K, Wallentin L, Lindhagen L, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. Eur Heart J. 2017;38(41):3056-3065. doi: 10.1093/eurheartj/ehx515
- Golla MSG, Shams P. Heart Failure With Preserved Ejection Fraction (HFpEF). In: StatPearls. Treasure Island (FL): StatPearls Publishing; March 19, 2024.
- Kaddoura R, Patel A. Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction. Curr Probl Cardiol. 2023; 48(12): 102015. doi: 10.1016/j.cpcardiol.2023.102015
- Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018; 39(1): 26-35. doi: 10.1093/eurheartj/ehx564
- Fukuta H, Goto T, Wakami K, et al. Effect of beta-blockers on heart failure severity in patients with heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Heart Fail Rev. 2021;26(1):165-171. doi: 10.1007/s10741-020-10013-5
- Arnold SV, Silverman DN, Gosch K, et al. Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction. JACC Heart Fail. 2023;11(8 Pt 1):893-900. doi: 10.1016/j.jchf.2023.03.017
- Munkhaugen J, Ruddox V, Halvorsen S, et al. BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study. Am Heart J. 2019;208:37-46. doi: 10.1016/j.ahj.2018.10.005
- Rossello X, Raposeiras-Roubin S, Latini R, et al. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). Eur Heart J Cardiovasc Pharmacother. 2022;8(3):291-301. doi: 10.1093/ehjcvp/pvab060
- Sean van Diepen, Sigrun Halvorsen, Venu Menon, The REDUCE-AMI trial: an important step in cardiovascular drug de-prescription, European Heart Journal. Acute Cardiovascular Care. 2024; 13 (4): 370–372. doi: 10.1093/ehjacc/zuae049.
- Kristensen AMD, Bovin A, Zwisler AD, et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. Trials. 2020; 21(1): 415. doi: 10.1186/s13063-020-4214-6
- Silvain J, Cayla G, Ferrari E, et al. βeta blocker interruption after uncomplicated myocardial infarction: rationale and design of the randomized ABYSS trial. Am Heart J. 2023; 258: 168-176. doi: 10.1016/j.ahj.2023.01.014
- Joo SJ, Kim SY, Choi JH, et al. Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2021; 7(6): 475-482. doi: 10.1093/ehjcvp/pvaa029
- Dondo TB, Hall M, West RM, et al. β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. J Am Coll Cardiol. 2017; 69(22): 2710-20. doi: 10.1016/j.jacc.2017.03.578
- Wahlberg K, Arnold ME, Lustgarten D, et al. Effects of a Higher Heart Rate on Quality of Life and Functional Capacity in Patients With Left Ventricular Diastolic Dysfunction. Am J Cardiol. 2019;124(7):1069-1075. doi: 10.1016/j.amjcard.2019.07.008
- Российское кардиологическое общество. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(11):4083. [Russian Society of Cardiology. Chronic heart failure. Clinical guidelines 2020. Russian Journal of Cardiology. 2020; 25(11):4083 (in Russ.)]. doi: 10.15829/1560-4071-2020-4083.
- Horiuchi Y, Tanimoto S, Aoki J, et al. Effects of β-blockers on left ventricular remodeling in patients with preserved ejection fraction after acute myocardial infarction. Int J Cardiol. 2016;221:765-769. doi: 10.1016/j.ijcard.2016.07.123
- Conraads VM, Metra M, Kamp O, et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail. 2012;14(2):219-225. doi: 10.1093/eurjhf/hfr161
- Закиев В.Д., Воробьёва Н.М., Малая И.П. и др. Бета-блокаторы при хронической сердечной недостаточности с сохранной фракцией выброса левого желудочка: возможен ли депрескрайбинг? Рациональная Фармакотерапия в Кардиологии. 2023;19(6):607-613. [Zakiev V.D., Vorobyeva N.M., Malaya I.P. and others. Beta blockers in chronic heart failure with preserved left ventricular ejection fraction: is deprescribing possible? Rational Pharmacotherapy in Cardiology. 2023;19(6):607-613 (in Russ.)]. doi: 10.20996/1819-6446-2023-2987.
- Palau P, Seller J, Domínguez E, et al. Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction [published correction appears in J Am Coll Cardiol. 2022 Mar 1;79(8):848. doi: 10.1016/j.jacc.2022.01.012]. J Am Coll Cardiol. 2021;78(21):2042-2056. doi: 10.1016/j.jacc.2021.08.073
- M Seo, T Watanabe, T Yamada, et al. The clinical relevance of quality of life in patients with acute decompensated heart failure with preserved ejection fraction: insights from the PURSUIT-HFpEF Registry, European Heart Journal. 2022: 43 (2): 1059. doi: 10.1093/eurheartj/ehac544.1059
- Silverman DN, Plante TB, Infeld M, et al. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial. JAMA Netw Open. 2019; 2(12): e1916598. doi: 10.1001/jamanetworkopen.2019.16598
- Frenneaux MP. Autonomic changes in patients with heart failure and in post-myocardial infarction patients. Heart. 2004;90(11):1248-1255. doi: 10.1136/hrt.2003.026146
- Saleem S, Khandoker AH, Alkhodari M, et al. Investigating the effects of beta-blockers on circadian heart rhythm using heart rate variability in ischemic heart disease with preserved ejection fraction. Sci Rep. 2023; 13(1):5828. doi: 10.1038/s41598-023-32963-0
- Troels Yndigegn, M.D., Bertil Lindahl, Ph.D., Katarina Mars, M.D., et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. April 7, 2024 N Engl J Med 2024;390:1372-1381 doi: 10.1056/NEJMoa2401479.
Supplementary files
